Cancer Therapy News and Research

RSS

Scientists combine new type of nanoparticle with photodynamic therapy to kill cancer cells

An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors.

16 Oct 2014

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

13 Oct 2014

Pharmaceutical industry withdraws from the antibiotic space

The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive.

13 Oct 2014

Research roundup: Older consumers' spending on health care; hospital leaders' views of reporting quality

In 2011, households with at least one member between ages 50 and 64 spent 8 percent of their total budget on health items, compared with 19 percent for those age 85 or over.

13 Oct 2014

Blocking STAT3 in immune system cells increases anti-tumour immunity

The STAT transcription factors are involved in the development of many forms of cancer. STAT3 is frequently activated in tumour cells, so drugs targeting STAT3 could be used in cancer therapy. However, STAT3 is also important in the development of the immune system. Dagmar Gotthardt and colleagues at the Vetmeduni Vienna now show that blocking STAT3 in cells of the immune system actually leads to increased anti-tumour immunity. Anti-STAT3 therapy may thus be highly promising.

13 Oct 2014

Champalimaud Foundation to establish cancer institute in Rajasthan, India

The Lisbon based Champalimaud Foundation has entered into a partnership with the Government of Rajasthan, India, to establish a state-of-the–art cancer institute with world-class facilities.

12 Oct 2014

Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

Pancreatic cancer is one of the deadliest cancers. Even with aggressive treatment, the prognosis is poor, with various factors stacking the odds against successful treatment: early detection is uncommon, it tends to spread quickly and recurrence is likely. However, several newer approaches show promise in increasing the response rate to pancreatic cancer treatment.

10 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Tel Aviv University researcher advances novel strategy to fight cancer by shoring up the immune system

Two years ago, Prof. Eshel Ben-Jacob of Tel Aviv University's School of Physics and Astronomy and Rice University's Center for Theoretical Biological Physics made the startling discovery that cancer, like an enemy hacker in cyberspace, targets the body's communication network to inflict widespread damage on the entire system.

8 Oct 2014

'Achilles heel' in metabolic pathway could stop growth of lung cancer cells

Researchers at UT Southwestern Medical Center have found an "Achilles heel" in a metabolic pathway crucial to stopping the growth of lung cancer cells.

8 Oct 2014

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech.

7 Oct 2014

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy.

7 Oct 2014

UNM Cancer Center surgeon receives NCI's Cancer Clinical Investigator Team Leadership Award

Surgeon Teresa Rutledge, MD, recently received the National Cancer Institute's Cancer Clinical Investigator Team Leadership Award. Only 11 people nationwide received the award this year. Dr. Rutledge is the third faculty member in the history of the University of New Mexico Cancer Center to be recognized with this honor.

7 Oct 2014

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

6 Oct 2014

Scientists shed new light on how LAMR1 and Gal-3 proteins can cause meningitis, septicaemia

Previously undiscovered secrets of how human cells interact with a bacterium which causes a serious human disease have been revealed in new research by microbiologists at The University of Nottingham.

5 Oct 2014

CTRC researcher receives special $1.62 million orphan disease grant from FDA

A researcher at the Cancer Therapy & Research Center is the leader on a study receiving a special $1.62 million orphan disease grant from the Food & Drug Administration.

5 Oct 2014

Aflac announces new campaign to support National Breast Cancer Awareness Month

Aflac, the leading provider of voluntary insurance in the United States, announced a new campaign aimed at helping stamp out breast cancer during National Breast Cancer Awareness Month, with net proceeds going to the American Association for Cancer Research Foundation.

3 Oct 2014

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, today announces that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014.

3 Oct 2014

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Columbia University will award the 2014 Louisa Gross Horwitz Prize to James P. Allison, PhD, of the University of Texas MD Anderson Cancer Center, for his work on understanding the process of T-cell activation and for developing therapies that harness the immune system to fight cancer.

3 Oct 2014

Majority of cancer survivors not financially prepared for cancer diagnosis, treatment

The majority (62%) of America's middle-income cancer survivors say they were not financially prepared for cancer diagnosis and treatment, according to a new study released by the Washington National Institute for Wellness Solutions.

30 Sep 2014

Cancer Therapy News and Research

Scientists combine new type of nanoparticle with photodynamic therapy to kill cancer cells

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Pharmaceutical industry withdraws from the antibiotic space

Research roundup: Older consumers' spending on health care; hospital leaders' views of reporting quality

Blocking STAT3 in immune system cells increases anti-tumour immunity

Champalimaud Foundation to establish cancer institute in Rajasthan, India

Recent clinical study sheds light on potential approach to more personalized care for pancreatic cancer

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Tel Aviv University researcher advances novel strategy to fight cancer by shoring up the immune system

'Achilles heel' in metabolic pathway could stop growth of lung cancer cells

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

UNM Cancer Center surgeon receives NCI's Cancer Clinical Investigator Team Leadership Award

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Scientists shed new light on how LAMR1 and Gal-3 proteins can cause meningitis, septicaemia

CTRC researcher receives special $1.62 million orphan disease grant from FDA

Aflac announces new campaign to support National Breast Cancer Awareness Month

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Majority of cancer survivors not financially prepared for cancer diagnosis, treatment

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News